Daiichi Sankyo (4568.T)

Executive Summary

Daiichi Sankyo has transformed into a global oncology leader, driven by its proprietary DXd antibody-drug conjugate (ADC) technology. Its flagship product, Enhertu (trastuzumab deruxtecan), has achieved blockbuster status in HER2-positive and HER2-low breast cancer, and the company continues to expand its ADC pipeline with datopotamab deruxtecan (Dato-DXd) targeting TROP2 and other novel ADCs. With a strong commercial portfolio that also includes established cardiovascular drugs like olmesartan and prasugrel, Daiichi Sankyo is well-positioned for sustained growth. The company's robust pipeline includes multiple Phase 3 trials across breast, lung, and gastric cancers, leveraging its ADC platform to address high unmet needs. Financially, Daiichi Sankyo is publicly traded (4568.T) with a market capitalization exceeding $450 billion, reflecting investor confidence in its oncology franchise and R&D productivity. Key near-term catalysts include regulatory decisions for Dato-DXd in breast cancer and potential label expansions for Enhertu, which could drive significant revenue upside.

Upcoming Catalysts (preview)

• Q3 2026FDA decision on datopotamab deruxtecan (Dato-DXd) for HR+/HER2- breast cancer75% success
• Q2 2026Phase 3 TROPION-Lung01 overall survival data for Dato-DXd in non-small cell lung cancer60% success
• TBDEnhertu label expansion into HER2-low gastric cancer (DESTINY-Gastric01 update)70% success